Spots Global Cancer Trial Database for Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
Official Title: A Study of Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
Study ID: NCT02343718
Study Description
Brief Summary: The purpose of this study is to determine the best dose of vinblastine that can be given with a new drug, temsirolimus.
Detailed Description: Vinblastine is already approved in the treatment of some types of cancer in children and temsirolimus is already used to treat some adult cancers in Canada. Temsirolimus has been shown to slow the growth of tumours in animals but it is not known if it can also slow tumour growth in children. Laboratory studies suggest that giving both vinblastine and temsirolimus may offer better results than giving vinblastine alone.
Keywords
Eligibility
Minimum Age: 1 Year
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Children's and Women's Health Centre of BC Branch, Vancouver, British Columbia, Canada
Izaak Walton Killam (IWK) Health Centre, Halifax, Nova Scotia, Canada
McMaster Children's Hospital, Hamilton, Ontario, Canada
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
Hospital for Sick Children, Toronto, Ontario, Canada
CHU Sainte-Justine, Montreal, Quebec, Canada
Contact Details
Name: Sylvain Baruchel
Affiliation: Hospital for Sick Children, Toronto ON Canada
Role: STUDY_CHAIR
Name: Rebecca Deyell
Affiliation: Children's & Women's Health Centre of BC Branch, Vancouver BC, Canada
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
